Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab versus secukinumab in moderate to severe chronic plaque psoriasis
2017-003784-35Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in psoriasis (2 arms), sponsored by UCB. Primary endpoint: PASI100 response at Week 16. Started Apr 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2017-003784-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003784-35.